摘要
经导管主动脉瓣置换术(Transcatheter Aortic Valve Replacement, TAVR)彻底改变了主动脉瓣狭窄(Aortic Stenosis, AS)患者的治疗方法,多项随机试验显示了其在高、中、低手术风险严重主动脉瓣狭窄患者中的安全性和有效性,因此,美国和欧洲的心脏瓣膜病管理及治疗指南扩大了TAVR的适应症,随后全球每年的TAVR手术数量呈指数级增长。尽管经导管主动脉瓣置换术最初是为了满足老年人群中三叶式主动脉瓣狭窄未满足的临床需求,但随着TAVR的迅猛发展,其用途已逐渐扩展到其他主动脉瓣病变患者群体,例如二叶式主动脉瓣狭窄、生物瓣衰败和重度纯主动脉瓣反流患者,在本综述中,我们将重点关注单纯自体主动脉瓣反流(Pure Native Aortic Regurgitation, PNAR)TAVR治疗的进展。
Transcatheter aortic valve replacement(TAVR)has completely changed the treatment of patients with aortic stenosis(AS),and a number of randomized trials have shown its safety and efficacy in patients with severe aortic stenosis with high,medium and low surgical risk.Therefore,the guidelines for the management and treatment of valvular heart disease in the United States and Europe expand the indications of TAVR.Since then,the number of TAVR worldwide has increased exponentially every year.Although transcatheter aortic valve replacement was originally designed to meet the unmet clinical needs of tricuspid aortic stenosis in the elderly,with the rapid development of TAVR,its usage has gradually expanded to other groups of patients with aortic disease,such as bicuspid aortic stenosis,failing surgical bioprosthetic valves and severe pure aortic regurgitation.We focused on the progress of treatment of pure native aortic regurgitation(PNAR)with TAVR in this review.
作者
梁诚
汤圣兴
张云龙
张璇
Liang Cheng;Tang Shengxing;Zhang Yunlong;Zhang Xuan(The First Affiliated Hospital of Wannan Medical College(Yijishan Hospital of Wannan Medical College),Wuhu,Anhui 241001,China)
出处
《齐齐哈尔医学院学报》
2025年第11期1086-1090,共5页
Journal of Qiqihar Medical University
基金
安徽省教育厅重大项目(2023AH0402580)
安徽省重点研究与开发计划临床医学研究转化专项(202304295107020008)
皖南医学院重点项目科研基金(WK2023ZZD24)
芜湖市卫健委重点科研项目(WHWJ2023z004)
安徽省教育厅优秀青年项目(2023AH030103)。
关键词
主动脉瓣反流
主动脉瓣关闭不全
经导管主动脉瓣置换术
治疗进展
Aortic valve regurgitation
Aortic valve insufficiency
Transcatheter aortic valve Rrplacement
Treatment progress
作者简介
通信作者:张璇,Email:zhangxuan0819@163.com。
